EUVIMEDEUVIMED entdecken
Crossref

Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species‐mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin‐resistant colorectal cancer cells

Zhengguang Zhang iD, Cunsi Shen, Fuqiong Zhou, Yajie Zhang

Drug Development Research · 2023

DOI: 10.1002/ddr.22044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2023. Verfasst von Zhengguang Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Naphthoquinones, Colorectal Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxaliplatin (OXA) has been recognized as a third‐generation platinum‐based chemotherapeutic agent with stellar therapeutic efficacy in managing colorectal cancer (CRC). Nevertheless, resistance to OXA in CRC patients hinders its effectiveness. Shikonin (SHI), a natural naphthoquinone derived from Arnebia euchroma (Royle) Johnst. , features a broad pharmacological profile and minimal toxicities. To assess the synergism of SHI and OXA towards OXA‐resistant CRC cells (HCT116 R ), we employed in vitro and in vivo pharmacological assays. Our experiments provided evidence that SHI, either alone or in combination with OXA, considerably reduced cell proliferation, triggered apoptosis, and induced the generation of reactive oxygen species (ROS) in HCT116 R cells. Furthermore, the combination of SHI and OXA dramatically curbed the extent of HCT116 R ‐initiated xenograft growth in mouse models. Bioinformatics, western blot, and ROS assays highlighted that the mechanisms of SHI against OXA‐resistant CRC cells may involve the induction of cellular responses to chemical stress, intrinsic apoptosis, as well as endoplasmic reticulum stress pathways mediated by ROS. Notably, the synergism of SHI+OXA was partially abrogated by an ROS inhibitor N‐acetyl cysteine. Our findings imply the potential of SHI to boost the sensitivity of OXA to CRC, offering promising benefits for clinical strategies to combat OXA resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaphthoquinonesColorectal NeoplasmsAnimalsMiceHumansOxaliplatinReactive Oxygen SpeciesApoptosisCell Line, TumorEndoplasmic Reticulum Stress

Stichwörter der Autor:innen

Shikonincombination treatmentoxaliplatinoxaliplatin-resistant colorectal cancer

Substanzen

OxaliplatinReactive Oxygen SpeciesshikoninNaphthoquinones

Autor:innen und Institutionen

  • School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
  • Central Laboratory, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.

ORCID-Profile: Zhengguang Zhang

Zitieren

APA

Zhang, Z., Shen, C., Zhou, F., & Zhang, Y. (2023). Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species‐mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin‐resistant colorectal cancer cells. Drug Development Research. https://doi.org/10.1002/ddr.22044

Vancouver

Zhang Z, Shen C, Zhou F, Zhang Y. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species‐mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin‐resistant colorectal cancer cells. Drug Development Research. 2023. doi:10.1002/ddr.22044

BibTeX
@article{Zhang2023,
  author = {Zhang, Zhengguang and Shen, Cunsi and Zhou, Fuqiong and Zhang, Yajie},
  title = {Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species‐mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin‐resistant colorectal cancer cells},
  journal = {Drug Development Research},
  year = {2023},
  doi = {10.1002/ddr.22044}
}
Kostenlos starten →